orelabrutinib

Orelabrutinib is a highly selective, irreversible small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed primarily for the treatment of B-cell malignancies and autoimmune diseases. By binding to and inhibiting BTK, orelabrutinib blocks B-cell receptor signaling and downstream survival pathways, leading to inhibition of malignant B-cell growth. It demonstrates high selectivity for BTK with minimal off-target activity against other kinases. Orelabrutinib has been approved in China for relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). It is also under investigation in multiple global clinical trials for indications including Waldenström's macroglobulinemia, diffuse large B cell lymphoma, idiopathic thrombocytopenic purpura, multiple sclerosis, neuromyelitis optica spectrum disorder, systemic lupus erythematosus, and other lymphomas[1][3][4][7][8].

Brand names

INNOBRUKAYINUOKAI

Other names

orelabrutinib [INN]orelabrutinib [USAN]